Back to Journals » Pragmatic and Observational Research » Volume 3

Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease

Authors Martin-Merino E, Johansson, Bueno, Garcia Rodriguez

Received 28 December 2011

Accepted for publication 7 February 2012

Published 16 March 2012 Volume 2012:3 Pages 1—9

DOI https://doi.org/10.2147/POR.S29557

Review by Single-blind

Peer reviewer comments 3


Elisa Martín-Merino1, Saga Johansson2, Héctor Bueno3, Luis A García Rodríguez1

1Spanish Centre for Pharmacoepidemiologic Research (CEIFE), Madrid, Spain; 2AstraZeneca R&D, Mölndal, Sweden; 3Department of Cardiology, Hospital General Universitario Gregorio Marañón, Madrid, Spain

Background: Discontinuation of low-dose acetylsalicylic acid (ASA) leads to an increased risk of cardiovascular and cerebrovascular events in patients taking low-dose ASA for secondary cardiovascular prevention. However, little is known about the rate of discontinuation in everyday clinical practice.
Objectives: To assess the rate of low-dose ASA discontinuation in primary care, and identify factors that predict discontinuation.
Methods: The Health Improvement Network, a large UK primary care database, was used to identify patients aged 50–84 years who received at least two consecutive prescriptions for low-dose ASA for secondary cardiovascular or cerebrovascular prevention in 2000–2007 (n = 35,639). Discontinuation was defined as a period of at least 90 days after completion of the last prescribed course of ASA during which no repeat prescription was issued.
Results: During the study, 11,729 patients (32.9%) discontinued ASA therapy (mean follow-up 2.5 years). The discontinuation rate was lower in patients with ASA indicated for myocardial infarction than for other indications. The diagnosis of gastrointestinal disorders during the study (overall odds ratio: 1.74; 95% confidence interval: 1.61–1.88) was associated with increased rates of ASA discontinuation, whereas co-prescription of a proton pump inhibitor from the start of ASA therapy was associated with a decreased rate of discontinuation (odds ratio: 0.80; 95% confidence interval: 0.75–0.86). Co-prescription of several other cardioprotective medications was also associated with a reduced risk of discontinuation, as were increasing age, prior hospitalization and overall number of co-medications.
Conclusion: Continuous co-prescription of a PPI with low-dose ASA may improve adherence and outcomes, particularly in patients at both cardiovascular and gastrointestinal risk.

Keywords: aspirin, primary health care, compliance

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]